Effect of an oral gold compound, auranofin, on non-specific bronchial hyperresponsiveness in mild asthma.
AUTOR(ES)
Honma, M
RESUMO
BACKGROUND--A recent double blind clinical trial in Japan has shown that auranofin (6 mg/day) is a useful treatment for patients with moderate to severe asthma. To investigate the mechanism of action of auranofin the bronchial responsiveness to inhaled methacholine has been studied in well controlled asthmatic subjects. METHODS--Nineteen adult asymptomatic asthmatic subjects received auranofin (3 mg orally twice a day) or inactive placebo in random order for 12 weeks in a double blind fashion. Bronchial responsiveness to inhaled methacholine and pulmonary function tests were measured at the same time on different days before, and six and 12 weeks after, each treatment. RESULTS--Non-specific bronchial hyperresponsiveness 12 weeks after treatment with auranofin was decreased compared with that before treatment with auranofin and 12 weeks after treatment with inactive placebo, although the treatment did not improve pulmonary function tests. CONCLUSIONS--Non-specific bronchial hyperresponsiveness 12 weeks after treatment with auranofin is decreased in a group of mild asymptomatic asthmatic patients with normal lung function.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=475050Documentos Relacionados
- Long term study of the effect of sodium cromoglycate on non-specific bronchial hyperresponsiveness.
- Increase in non-specific bronchial hyperresponsiveness as an early marker of bronchial response to occupational agents during specific inhalation challenges.
- Seasonal variation in non-specific bronchial reactivity: a study of wheat workers with a history of wheat associated asthma.
- Tea asthma: response to specific and non-specific challenges.
- Non-specific effects of vaccination: Vaccines have non-specific (heterologous) effects